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background:  Although testosterone deficiency is associated with increased risks of heart disease, benefits of testosterone replacement therapy is 
controversial. Currently, the cardiac effect of testosterone during cardiac ischemia-reperfusion (I/R) periods is also unclear. We tested the hypothesis 
that testosterone replacement attenuates the impairment of left ventricular (LV) functions, heart rate variability (HRV) and reduces the infarct size 
and arrhythmias caused by I/R injury.
Method: Orchiectomized (ORX) or sham-operated male Wistar rats (n=24) were randomly divided to receive either testosterone (2 mg/kg, sc) or 
vehicle for 8 weeks. The ejection fraction (EF) and HRV were determined at baseline, 4th and 8th week. I/R was performed by 30 minutes of LAD 
ligation, followed by 120-minute reperfusion. LV pressure, arrhythmia scores and infarct size were determined.
Result: In ORX rats (serum testosterone=0.03 ng/ml), EF and HRV were impaired, but were restored in testosterone-treated group (serum 
testosterone=3.6±0.5 ng/ml). Arrhythmia score and infarct size were significantly greater, whereas the time to 1st VT/VF onset, and the LV end 
systolic pressure were significantly decreased, compared to the sham group (serum testosterone=3.3±0.6 ng/ml). Testosterone therapy attenuated 
the impairment of these parameters in ORX rats (Figure).
Conclusion: Testosterone replacement restores LV function and HRV in ORX rats, and exerts cardioprotective effect during I/R period in ORX rats.
